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Recurring gastrointestinal stromal tumor with splenic 
metastasis
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1Pathology, Chonnam National University Medical School, 
Gwangju, Korea
Malignant gastrointestinal stromal tumors (GISTs) are rare non-epithelial, mesenchymal neoplasms of the gastrointestinal 
tract that metastasize or recur in 30% of patients who undergo surgical resection with curative intent. A 59-year-old man vis-
ited our hospital for an examination of a palpable mass in the left abdomen. Fourteen months prior to his visit, the patient un-
derwent gastric wedge resection to remove a GIST of the gastric cardia. At the time of surgery, no evidence of metastatic dis-
ease was observed and the pathological interpretation was a high-risk GIST. A follow-up computed tomography scan of the 
abdomen revealed a partially necrotic solid mass (9.8 × 7.6 cm) and enhancing mass in the spleen (2.3 cm). On exploration, 
multiple masses were found in the liver, greater omentum, and mesentery. Here, we report a case of recurring GIST of the 
stomach that metastasized to the spleen. To the best of our knowledge, few reports of metastasis to the spleen exist.
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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are thought to 
arise from the interstitial cells of Cajal (ICC), which func-
tion as gastrointestinal pacemaker cells [1]. GISTs exhibit a 
wide clinical spectrum, from benign to frankly malignant, 
and more than 30% of the patients with malignant tumors 
develop local recurrence and distant metastases who un-
dergo resection with curative intent [2]. The most common 
metastatic site is the liver (65%) [3]. To the best of our 
knowledge, rare reports of metastasis to the spleen exist. 
Here, we document a case of recurring GIST of the stom-
ach that metastasized to the spleen.
CASE REPORT
A 59-year-old man visited our hospital for an examina-
tion of a palpable mass in the left abdomen. Fourteen 
months prior to his visit, the patient underwent gastric 
wedge resection to remove a GIST of the gastric cardia 
(Fig. 1). At the time of surgery, no evidence of metastatic 
disease was observed and the pathological interpretation 
was a high-risk GIST. A follow-up computed tomography 
(CT) scan of the abdomen revealed a partially necrotic sol-
id mass (9.8 × 7.6 cm) and enhancing mass in the spleen (2.3 
cm) (Fig. 2). Two masses (8.3 × 5.5 cm, 10.7 × 8.5 cm) were 
also found in the liver. Laparoscopic examination in-Ho Gun Kim, et al.
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Fig. 1. A 4 × 3.5 cm sized ovoid shaped mass covered with intact 
mucosa except small ulceration in the gastric cardia on upper 
gastrointestinal endoscopy.
Fig. 2. Follow-up computed tomography shows metastasized mass 
in the spleen.
dicated peritoneal seeding, and palliative surgery (com-
pletion gastrectomy, splenectomy, omentectomy, and left 
hepatectomy) was performed.
Upon macroscopic examination, a 0.8-cm tumor was 
found in the stomach of the cardia, 2.3 cm distal to the 
proximal margin, and two partially necrotic masses were 
detected in the liver and spleen (13.5 × 10.7 cm and 12.2 × 11 
cm, respectively) (Fig. 3). A histopathological examination 
revealed that the stomach tumor was composed of spin-
dle-shaped cells with numerous mitoses (＞10 mitoses per 
50 HPF) (Fig. 4). Almost all cells showed immunor-
eactivity for c-kit and CD34, but not for α-smooth muscle 
actin, S-100, or desmin. The histology of the masse in the 
spleen was similar to that of the gastric lesion. After sur-
gery, he received chemotherapy with imatinib mesylate (a 
single daily oral dose of imatinib 400 mg) and showed a 
high response. There was no recurred mass on follow-up 
CT. He is alive at this time (6 years after 2nd operation).
DISCUSSION
ICC, the intestinal pacemaker cells, may share the same 
nonneoplastic progenitor cells as GISTs; these tissues 
show ultrastructural similarities in terms of smooth mus-
cle and neural differentiation [1,2,4]. Most GISTs (50 to 
72%) show positive staining for CD34, but immunohisto-
chemical staining for KIT (CD117) is a more specific diag-
nostic criterion [4,5]. About 5% of GISTs are so-called wild-
type GISTs but still express the KIT receptor. These Recurring gastrointestinal stromal tumor
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Fig. 3. Intraoperative 
photograph of mass in 
the stomach and meta-
stasized masses in the 
spleen.
Fig. 4. Tumor of the 
stomach was compo-
sed of spindle-shaped 
cells with numerous 
mitoses (more than 10 
mitoses per 50 HPF) (A, 
B). Almost all of the cells 
showed immunoreacti-
vity for c- kit and CD34 
(C, D).Ho Gun Kim, et al.
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CD117-negative tumors often show other mutations in 
platelet-derived growth factor receptor-A, another ty-
rosine kinase [5].
GISTs may occur anywhere along the length of the di-
gestive tract, from the esophagus to the anus. Approxi-
mately 60 to 70% of GISTs arise in the stomach, 20 to 30% 
in the small intestine, 5% in the colon and rectum [1]. 
Early-stage GISTs often do not present any symptoms. 
Because most GISTs show an exophytic growth pattern 
and arise within the muscularis propria of the stomach or 
intestinal wall, they present as dominant masses outside 
of the organ of origin [4]. True GISTs can be identified from 
other tumors by histological analysis and the expression of 
KIT (CD117) and CD34 [3,5]. Although GISTs are gen-
erally fragile and soft, creating a high possibility of bleed-
ing, rupture, and tumor dissemination, preoperative his-
tological confirmation is generally warranted for poten-
tially resectable tumors whenever possible without major 
complications.
Among the various parameters used to predict clinical 
behavior, mitotic index and tumor size are considered to 
be the most reliable prognostic indicators [1,6]; tumor size, 
in particular, shows strong associations with survival and 
recurrence. According to Fletcher et al. [7], GISTs can be 
divided into categories based on size and mitoses: very 
low risk, low risk, intermediate risk, and high risk. Bucher 
et al. [8] proposed a revised classification of GISTs accord-
ing to malignancy and other parameters discussed in the 
literature. This revised scale includes five minor criteria 
and two major criteria. GISTs exhibiting fewer than four 
minor criteria are considered of low malignant potential, 
whereas GISTs that show four or five minor criteria or one 
major criterion are classified as high malignant potential, 
for which the 5-year survival rate is less than 20%.
The principal treatment modality for patients with pri-
mary GIST is complete surgical resection. Lymphadenec-
tomy is not routinely performed in patients with GIST 
[4,9]. Recurrent disease, however, is a serious problem, 
and the preferred treatment modality for recurrent tumors 
is to treat with drug. GIST patients also benefit from drug 
therapy using the specific molecular inhibitor, imatinib 
mesylate (Gleevec). This therapy is beneficial in un-
resectable diseases, as well as an adjuvant therapy after the 
resection of primary GIST [1,9,10]. Although complete re-
covery was not achieved, the patients showed a significant 
response with imatinib mesylate. In spite of clear surgical 
margins and no definite capsular tearing during the first 
operation, initial wedge resection was failed in this case. 
Capsular tearing and tumor seeding could be the causes of 
treatment failure during initial operation. So, surgeons 
should be careful not to occur capsular tearing and tumor 
seeding to prevent the recurrence. 
Here, we report a case of recurring GIST of the stomach 
that metastasized to the spleen and the liver. To the best of 
our knowledge, rare reports of metastasis to the spleen 
exist.
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